NASDAQ:AKLI Akili (AKLI) Stock Price, News & Analysis $0.43 0.00 (0.00%) (As of 07/2/2024) Add Compare Share Share Today's Range$0.43▼$0.4350-Day Range$0.41▼$0.4452-Week Range$0.19▼$1.25VolumeN/AAverage Volume2.20 million shsMarket Capitalization$34.01 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Akili alerts: Email Address Akili MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside825.9% Upside$4.00 Price TargetShort InterestHealthy0.67% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.53) to ($0.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.88 out of 5 starsMedical Sector434th out of 936 stocksSurgical & Medical Instruments Industry57th out of 101 stocks 3.5 Analyst's Opinion Consensus RatingAkili has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAkili has received no research coverage in the past 90 days.Read more about Akili's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.67% of the float of Akili has been sold short.Short Interest Ratio / Days to CoverAkili has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akili has recently decreased by 56.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkili does not currently pay a dividend.Dividend GrowthAkili does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AKLI. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Akili this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Akili to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akili insiders have not sold or bought any company stock.Percentage Held by Insiders10.10% of the stock of Akili is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.12% of the stock of Akili is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Akili's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Akili are expected to grow in the coming year, from ($0.53) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akili is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akili is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkili has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Akili's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Akili Stock (NASDAQ:AKLI)Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.Read More AKLI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKLI Stock News HeadlinesJuly 20, 2024 | americanbankingnews.comReviewing Akili (NASDAQ:AKLI) & DexCom (NASDAQ:DXCM)June 18, 2024 | businesswire.comAkili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video GameJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 14, 2024 | prnewswire.comAKILI INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akili, Inc. - AKLIJune 7, 2024 | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT, SGE on Behalf of ShareholdersJune 5, 2024 | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, WIRE on Behalf of ShareholdersJune 5, 2024 | globenewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. – AKLIJune 4, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. - AKLIJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 3, 2024 | businesswire.comAKLI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akili, Inc. Is Fair to ShareholdersMay 29, 2024 | bizjournals.comAkili to be delisted after getting acquiredMay 29, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Akili, Inc. has obtained a Fair Price for its Public ShareholdersMay 29, 2024 | businesswire.comPureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health CompanyMay 29, 2024 | businesswire.comVirtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health CompanyMay 15, 2024 | msn.comAkili reports Q1 results; suspends outlookMay 14, 2024 | investorplace.comAKLI Stock Earnings: Akili Beats EPS, Misses Revenue for Q1 2024May 14, 2024 | businesswire.comAkili Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 3, 2024 | bizjournals.comTherapeutic video game maker Akili lays off workers for third time in 16 monthsSee More Headlines Receive AKLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akili and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/27/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:AKLI CUSIPN/A CIK1850266 Webwww.akiliinteractive.com Phone650-931-6236FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+825.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,490,000.00 Net Margins-2,492.04% Pretax Margin-2,489.32% Return on Equity-79.93% Return on Assets-59.16% Debt Debt-to-Equity Ratio0.08 Current Ratio5.80 Quick Ratio5.80 Sales & Book Value Annual Sales$1.95 million Price / Sales17.46 Cash FlowN/A Price / Cash FlowN/A Book Value$0.75 per share Price / Book0.58Miscellaneous Outstanding Shares78,727,000Free Float70,776,000Market Cap$34.01 million OptionableOptionable Beta1.72 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Walter Edward Martucci II (Age 41)Ph.D., Co-Founder & Chairman Comp: $759.1kMr. Matthew Franklin M.B.A. (Age 50)President, CEO & Director Comp: $639.13kDr. Adam Gazzaley M.D. (Age 54)Ph.D., Co-Founder, Chief Science Advisor & Director Comp: $126.45kMs. Jacqueline L. Studer J.D. (Age 65)Chief Legal Officer, General Counsel & Secretary Comp: $559.55kMs. Caty ReidVP of Marketing & CommunicationsDr. Scott H. Kollins Ph.D.Chief Medical OfficerMr. Jonathan David (Age 46)Chief Product Officer More ExecutivesKey CompetitorsSemper Paratus AcquisitionNASDAQ:LGSTElectromedNYSE:ELMDFONARNASDAQ:FONRVivani MedicalNASDAQ:VANIPro-DexNASDAQ:PDEXView All CompetitorsInsiders & InstitutionsLongitude Cayman Ltd.Bought 150,000 shares on 5/10/2024Ownership: 0.445%Walter Edward Martucci IISold 2,353 sharesTotal: $2,470.65 ($1.05/share)Matthew FranklinSold 1,728 sharesTotal: $1,814.40 ($1.05/share)Jacqueline StuderSold 1,130 sharesTotal: $1,186.50 ($1.05/share)Santosh ShanbhagSold 830 sharesTotal: $871.50 ($1.05/share)View All Insider TransactionsView All Institutional Transactions AKLI Stock Analysis - Frequently Asked Questions How have AKLI shares performed this year? Akili's stock was trading at $0.4871 at the beginning of 2024. Since then, AKLI stock has decreased by 11.3% and is now trading at $0.4320. View the best growth stocks for 2024 here. How were Akili's earnings last quarter? Akili, Inc. (NASDAQ:AKLI) released its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.13) EPS for the quarter. The firm had revenue of $0.38 million for the quarter. Akili had a negative net margin of 2,492.04% and a negative trailing twelve-month return on equity of 79.93%. Who are Akili's major shareholders? Akili's top institutional shareholders include Concourse Financial Group Securities Inc.. Insiders that own company stock include Walter Edward Martucci II, Matthew Franklin, Jacqueline Studer and Santosh Shanbhag. View institutional ownership trends. How do I buy shares of Akili? Shares of AKLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AKLI) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akili, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akili With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.